Pro-osteogenic effects of fibrin glue in treatment of avascular necrosis of the femoral head in vivo by hepatocyte growth factor-transgenic mesenchymal stem cells

Journal of Translational Medicine

Li Ma¹  Mingqian Zhou¹  Wei Luo¹  Chaoying Zhou¹  Qian Wen¹ 

[1] Institute of Molecular Immunology, School of Biotechnology, Southern Medical University, #1838, Northern Guangzhou Ave, Guangzhou, Guangdong 510515, People’s Republic of China

关键词: Osteogenic regeneration;    Differentiation;    Proliferation;    Fibrin glue;    Mesenchymal stem cell;    Avascular necrosis of the femoral head;   

Others  :  814159
DOI  :  10.1186/1479-5876-12-114

 received in 2013-12-21, accepted in 2014-04-28,  发布年份 2014

【 摘 要 】

Background

Autologous transplantation of modified mesenchymal stem cells (MSCs) is a promising candidate for the treatment of the refractory clinical disease, avascular necrosis of the femoral head (ANFH). Our previous attempts by compounding MSCs with medical fibrin glue to treat ANFH in animal model have achieved excellent effects. However, the underlying molecular mechanism is unclear, especially on the transgenic gene expression.

Methods

Rabbit MSCs were isolated and compounded with fibrin glue. Following degrading of fibrin glue, proliferation, viability, expression of transgenic hepatocyte growth factor gene as well as osteogenic differentiation of MSCs were evaluated together with that of uncompounded MSCs. Fibrin glue-compounded MSCs were transplanted into the lesion of ANFH model, and the therapeutic efficacy was compared with uncompounded MSCs. One-Way ANOVA was used to determine the statistical significance among treatment groups.

Results

Fibrin glue compounding will not affect molecular activities of MSCs, including hepatocyte growth factor (HGF) secretion, cell proliferation and viability, and osteogenic differentiation in vitro. When applying fibrin glue-compounded MSCs for the therapy of ANFH in vivo, fibrin glue functioned as a drug delivery system and provided a sustaining microenvironment for MSCs which helped the relatively long-term secretion of HGF in the femoral head lesion and resulted in improved therapeutic efficacy when compared with uncompounded MSCs as indicated by hematoxylin-eosin staining and immunohistochemistry of osteocalcin, CD105 and HGF.

Conclusion

Transplantation of fibrin glue-compounding MSCs is a promising novel method for ANFH therapy.

【 授权许可】

   
2014 Wen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Jones L, Hungerford D: The pathogenesis of osteonecrosis. Instr Course Lect 2007, 56:179-196.
• [2]Mont M, Jones L, Hungerford D: Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 2006, 88:1117-1132.
• [3]Ito H, Matsuno T, Omizu N, Aoki Y, Minami A: Mid-term prognosis of non-traumatic osteonecrosis of the femoral head. J Bone Joint Surg (Br) 2003, 85:796-801.
• [4]Satija N, Gurudutta G, Sharma S, Gupta P, Verma YK, Singh VK, Tripathi RP: Mesenchymal stem cells: molecular targets for tissue engineering. Stem Cells Dev 2007, 16:7-23.
• [5]Gangji V, Hauzeur J, Matos C, De Maertelaer V, Toungouz M, Lambermont M: Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am 2004, 86:1153-1160.
• [6]Daltro GC, Fortuna VA, Araújo MAS, Lessa PIF, Batista Sobrinho UA, Borojevic R: Femoral head necrosis treatment with autologous stem cells in sickle cell disease. Acta Ortop Bras 2008, 16:23-27.
• [7]Wen Q, Jin D, Zhou CY, Zhou MQ, Luo W, Ma L: HGF-transgenic MSCS can improve the effects of tissue self-repair in a rabbit model of traumatic osteonecrosis of the femoral head. PLoS One 2012, 7:e37503.
• [8]Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schümichen C, Nienaber CA, Freund M, Steinhoff G: Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003, 361:45-46.
• [9]Sch Chinger V, Erbs S, Els Sser A, Haberbosch W, Hambrecht R, Lschermann H, Yu J, Corti R, Mathey DG, Hamm CW: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
• [10]Radosevich M, Goubran H, Burnouf T: Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 1997, 72:133-143.
• [11]Jackson MR, Friedman SA, Carter AJ, Bayer V, Burge JR, MacPhee MJ, Drohan WN, Alving BM: Hemostatic efficacy of a fibrin sealant-based topical agent in a femoral artery injury model: a randomized, blinded, placebo-controlled study. J Vasc Surg 1997, 26:274-280.
• [12]Marx G, Mou X: Characterizing fibrin glue performance as modulated by heparin, aprotinin, and factor XIII. Transl Res 2002, 140:152-160.
• [13]Bensaïd W, Triffitt J, Blanchat C, Oudina K, Sedel L, Petite H: A biodegradable fibrin scaffold for mesenchymal stem cell transplantation. Biomaterials 2003, 24:2497-2502.
• [14]Cox S, Cole M, Tawil B: Behavior of human dermal fibroblasts in three-dimensional fibrin clots: dependence on fibrinogen and thrombin concentration. Tissue Eng 2004, 10:942-954.
• [15]Mooney R, Tawil B, Mahoney M: Specific fibrinogen and thrombin concentrations promote neuronal rather than glial growth when primary neural cells are seeded within plasma-derived fibrin gels. Tissue Eng Part A 2010, 16:1607-1609.
• [16]Mogford J, Tawil B, Jia S, Mustoe T: Fibrin sealant combined with fibroblasts and platelet-derived growth factor enhance wound healing in excisional wounds. Wound Repair Regen 2009, 17:405-410.
• [17]Ho W, Tawil B, Dunn J, Wu B: The behavior of human mesenchymal stem cells in 3D fibrin clots: dependence on fibrinogen concentration and clot structure. Tissue Eng 2006, 12:1587-1595.
• [18]Catelas I, Dwyer J, Helgerson S: Controlled release of bioactive transforming growth factor beta-1 from fibrin gels in vitro. Tissue Eng Part C Methods 2008, 14:119-128.
• [19]Yau L, Molnar P, Moon M, Moon MC, Buhay S, Werner JP, Molnar K, Saward L, Del Rizzo D, Zahradka P: Meta-iodobenzylguanidine, an inhibitor of arginine-dependent mono (ADP-ribosyl) ation, prevents neointimal hyperplasia. J Pharmacol Exp Ther 2008, 326:717-724.
• [20]Breen A, Dockery P, O’Brien T, Pandit A: Fibrin scaffold promotes adenoviral gene transfer and controlled vector delivery. J Biomed Mater Res A 2009, 89:876-884.
• [21]Wen Q, Ma L, Chen Y, Yang L, Luo W, Wang X: Treatment of avascular necrosis of the femoral head by hepatocyte growth factor-transgenic bone marrow stromal stem cells. Gene Ther 2008, 15:1523-1535.
• [22]Wen Q, Zhou L, Zhou C, Zhou M, Luo W, Ma L: Change in hepatocyte growth factor concentration promote mesenchymal stem cell-mediated osteogenic regeneration. J Cell Mol Med 2012, 16:1260-1273.
• [23]Wen Q, Ma L, Chen Y, Yang L, Luo W, Wang X: A rabbit model of hormone-induced early avascular necrosis of the femoral head. Biomed Environ Sci 2008, 21:398-403.
• [24]Kusumi T, Kusumi A: Osteocalcin/bone Gla protein (BGP). Nihon Rinsho 2004, 62(Suppl 2):136-140.
• [25]Yin L, Li Y, Wang Y: Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures: mechanism of steroid-induced osteonecrosis. Chin Med J (Engl) 2006, 119:581-588.
• [26]Barbara N, Wrana J, Letarte M: Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999, 274:584-594.
• [27]Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O: Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 2006, 56:717-723.
• [28]Comoglio P: Pathway specificity for met signalling. Nat Cell Biol 2001, 3:E161-E162.
• [29]Spicer P, Mikos A: Fibrin glue as a drug delivery system. J Control Release 2010, 148:49-55.